Ada Health raises $47mn in new funding round
Raising $47 million in a latest funding round, Ada Health is soon to expand into new markets. Currently based in Europe, with locations in Berlin, Munich and London, the company is set to hire more staff and open up a new office in the US.
Since its launch, the health app has become one of the most popular and renowned healthcare tools on the app market and was downloaded over a million times six months after becoming established. Easy to use, it has become an essential tool worldwide, especially within countries where access to medical care is limited.
On their website. CEO of Ghana-based Vantage Medical Solutions Dr Byrite Asamoah has explained: “Many people in Africa do not have easy access to a doctor or medical information. Ada's innovative approach is helping to close this important gap.”
Daniel Nathrath, CEO and co-founder of Ada Health has said: “The future of healthcare lies in a much more patient-centric model where individuals have actionable insights at their fingertips, and doctors and artificial intelligence work together to support patients throughout their healthcare journey.”
- Amazon’s pharma ambitions ramp up, causing pharmacy distribution stocks to plunge
- MintHealth builds new personal health records using blockchain tech
- Huawei and Phillips will collaborate on a new cloud-based healthcare solution
Utilising AI and machine learning, users are able to describe their symptoms to a technological “doctor” or consultant on the app. This data is then analysed and then enables users to be connected to a medical professional to discuss further if required.
Guillaume d’Hauteville, Vice Chairman, Access Industries has said: Ada is one of the most exciting companies we've seen cutting across health and artificial intelligence. They have developed a unique and highly effective health management solution driven by a team with deep medical and AI expertise and years of technology development.”
Led by Len Blavatnik’s global investment company Access Industries, the funding round has attracted a number of influential investors who can see its long-term potential and ability to disrupt such a traditional industry.
Names of financial backers have been also created a significant buzz surrounding the technology. William Tunstall-Pedoe, who sold his virtual assistant technology to Amazon in order to create Alexa has interestingly highlighted his interest as a financial investor. Additionally, June Fund, which has Google Chief Business Officer Philipp Schlindler at the helm, has contributed significantly to the app’s development.
The investment round will enable Ada Health to further its growth, enter new markets, expand its skilled workforce and develop its service offerings.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”